Back
Compare AU
Compare CURE vs. GOVT
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the SPDR S&P/ASX Iboxx Australian Government Bond ETF (GOVT). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | GOVT | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 71 | 4 |
Median incremental investment | $654.83 | $125.75 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,386.48 | $3,403.13 |
Average age group | > 35 | > 35 |
Key Summary
CURE | GOVT | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | GOVT.AX was created on 2012-07-26 by SPDR. The fund's investment portfolio concentrates primarily on investment grade fixed income. The ETF currently has 67.54m in AUM and 115 holdings. The SPDR S&P/ASX iBoxx Australian Government Bond ETF seeks to closely track, before fees and expenses, the returns of the S&P/ASX iBoxx Australian & State Governments 0+ Index. |
Top 3 holdings | CRISPR Therapeutics AG (2.18 %) Revolution Medicines Inc Ordinary Shares (2.05 %) Exact Sciences Corp (1.99 %) | Australia (Commonwealth of) 2.75% (3.03 %) Australia (Commonwealth of) 2.75% (2.98 %) Australia (Commonwealth of) 3.25% (2.87 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.45 % | 0.1 % |
Key Summary
CURE | GOVT | |
|---|---|---|
Issuer | Global X | SPDR |
Tracking index | S&P Biotechnology Select Industry | S&P/ASX iBoxx Australian & State Governments 0+ Index - AUD - Benchmark TR Gross |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.1 % |
Price | $57.90 | $24.71 |
Size | $36.172 million | $68.560 million |
10Y return | N/A | -4.85 % |
Annual distribution yield (5Y) | 5.08 % | 1.77 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 27/07/2012 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | GOVT | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 71 | 4 |
Median incremental investment | $654.83 | $125.75 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,386.48 | $3,403.13 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | GOVT | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | GOVT |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |